Investor Presentaiton

19 Impact of COVID-19 and Recent Developments Shifted to a broad virtual sales program reaching thousands during web events and maintain remote contact with key accounts. Provided support to existing and new customers through remote proctoring for cases, web-based physician certification and educational seminars Gained increased attention to fit during COVID restrictions because procedure delivers strong efficacy, low risk and requires minimal follow up visits YTD net losses have decreased by $1.1 million to -$6.2 million from -$7.3 million in the period of 2019 Exited Q3 with CycloⓇ G6 probe sales achieving 106% of prior year Q3 IRIDEX

View entire presentation